Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2000-11-09
2008-12-02
Canella, Karen A. (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S388100, C530S388240, C530S389700
Reexamination Certificate
active
07459536
ABSTRACT:
The present invention provides a combination of anti-HGF/SF antibodies that specifically bind HGF/SF and inhibits HGF/SF activity. The present invention further provides a combination of anti-HGF/SF antibodies comprising three or more anti-HGF/SF antibodies selected from the group consisting of antibody #1 produced from hybridoma 1C10-F1-A11, antibody #4 produced from hybridoma 8H2-F2-B10, antibody #5 produced from hybridoma 13B1-E4-E10, antibody #7 produced from hybridoma 15D7-B2, and antibody #10 produced from hybridoma 31D4-C9-D4. The invention also provides a method of treating cancer in a subject comprising administering to the subject a combination of anti-HGF/SF antibodies whereby the antibodies bind to a hepatocyte growth factor, whereby the binding of the antibodies to a hepatocyte growth factor results in an inhibition of hepatocyte growth factor binding to the hepatocyte growth factor receptor, whereby the inhibition of hepatocyte growth factor binding to receptor causes an inhibition of cancer growth, thereby treating the cancer.
REFERENCES:
patent: 5646036 (1997-07-01), Schwall et al.
patent: 5707624 (1998-01-01), Nickoloff et al.
patent: 6852318 (2005-02-01), Varner
patent: WO 91/12272 (1991-08-01), None
patent: WO 94/06909 (1994-03-01), None
patent: WO 98/19696 (1998-05-01), None
Harlow and Lane(Antibodies, A Laboratory Manual, 1988, p. 141-142).
Colnaghi et al. (Current Opinion in Oncology, 1993, 5:1035-1042).
Bellusci et al., “Creation of a hepatocyte growth factor/scatter factor autocrine loop in carcinoma cells induces invasive properties associated with increased tumorigenicity,”Oncogene 9:1091-1099 (1994).
Bussolino et al., “Hepatocyte Growth Factor is a Potent Angiogenic Factor which Stimulates Endothelial Cell Motility and Growth,”J. Cell Biol. 119(3):629-641 (1992).
Chirgadze et al., “Crystal structure of the NK1 fragment of HGF/SF suggests a novel mode for growth factor dimerization and receptor binding,”Nat. Struct. Biol. 6(1):72-79 (1999).
Cooper et al., “Molecular cloning of a new transforming gene from a chemically transformed human cell line,”Nature 311(6):29-33 (1984).
Gherardi et al., “Hepatocyte Growth Factor/Scatter Factor (HGF/SF), The c-metReceptor and The Behaviour Epithelial Cells,”Soc. Exp. Biol. 47:163-181 (1993).
Giordano et al., “Transfer of motogenic and invasive response to scatter factor/hepatocyte growth factor by transfection of humanMETprotooncogene,”Proc. Natl. Acad. Sci 90:649-653 (1993).
Grant et al., “Scatter factor induces blood vessel formation in vivo,”Proc. Natl. Acad. Sci. 90:1937-1941 (1993).
Hartmann et al., “A functional domain in the heavy chain of scatter factor/hepatocyte growth factor binds the c-Metreceptor and induces cell dissociation but not mitogenesis,”Proc. Natl. Acad. Sci. 89:11574-11578 (1992).
Higashio et al., “Tumor cytotoxic activity of HGF/SF,”Exper. Suppl. 65:351-368 (1993).
Ichimura et al., “Expression of c-met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance,”Jpn. J. Cancer Res. 87:1063-1069 (1996).
Jeffers et al., “Hepatocyte growth factor/scatter factor-Met signaling in tumorigenicity and invasion/metastasis,”J. Mol. Med. 74:505-513 (1996).
Jeffers et al., “Autocrine hepatocyte growth factor/scatter factor-Met signaling induces transformation and the invasive/metastatic phenotype in C127 cells,”Oncogene 13:853-861 (1996).
Kenworthy et al., “The presence of scatter factor in patients with metastic spread to the pleura,”Br. J. Cancer 66:243-247 (1992).
Koochekpour et al., “The von Hippel-Lindau Tumor Suppressor Gene Inhibits Hepatocyte Growth Factor/Scatter Factor-Induced Invasion and Branching Morphogenesis in Renal Carcinoma Cells,”Mol. Cell. Biol. 19(9):5902-5912 (1999).
Koochekpour et al., “Met and Hepatocyte Growth Factor/Scatter Factor Expression in Human Gliomas,”Cancer Res. 57:5391-5398 (1997).
Lamszus et al., “Scatter Factor Promotes Motility of Human Glioma and Neuromicrovascular Endothelial Cells,”Int. J. Cancer 75:19-28 (1998).
Liu et al., “Proto-Oncogene and Growth Factor/Receptor Expression in the Establishment of Primary Human Non-small Cell Lung Carcinoma Cell Lines,”Am. J. Pathnol. 142(2):413-423 (1993).
Lokker et al., “Generation and Characterization of a Competitive Antagonist of Human Hepatocyte Growth Factor, HGF/NK1,”J. Biol. Chem. 268(23):17145-17150 (1993).
Matsumoto et al., “Cooperative interaction between α- and β-Chains of Hepatocyte Growth Factor on c-Met Receptor Confers Ligand-induced Receptor Tyrosine Phosphorylation and Multiple Biological Responses,”J. Biol. Chem. 273(36):22913-22920 (1998).
Matsumoto et al., “Roles of HGF as a pleiotropic factor in organ regeneration,” Birkhauser-Verlag, Basel (1993).
Matsumoto et al., “Deletion of Kringle Domains or the N-Terminal Hairpin Structure in Hepatocyte Growth Factor Results in Marked Decreases in Related Biological Activities,”Biochem. Biophys. Res. Comm. 181(2):691-699 (1991).
Matsumoto et al., “Hepatocyte Growth Factor: Molecular Structure, Roles in Liver Regeneration, and Other Biological Functions,”Crit. Rev. Oncog. 3(1,2):27-54 (1992).
Montesano et al., “Identification of a Fibroblast-Derived Epithelial Morphogen as Hepatocyte Growth Factor,”Cell 67:901-908 (1991).
Nakamura, “Structure and Function of Hepatocyte Growth Factor,”Prog. Growth Factor Res. 367-85 (1991).
Nusrat et al., “Hepatocyte Growth Factor/Scatter Factor Effects on Epithelia. Regulation of Intercellular Junctions in Transformed and Nontransformed Cell Lines, Basolateral Polarization of c-met Receptor in Transformed and Natural Intestinal Epithelia and Induction of Rapid Wound Repair in a Transformed Model Epithelium,”J. Clin. Invest. 93:2056-2065 (1994).
Okigaki et al., “Functional Charaacterization of Human Hepatocyte Growth Factor Mutants Obtained by Deletion of Structural Domains,”Biochemistry 31:9555-9561 (1992).
Rong et al., “Invasiveness and metastatis of NIH 373 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation,”Proc. Natl. Acad. Sci. 91:4731-4735 (1994).
Rong et al., “Met Proto-oncogene Product is Overexpressed in Tumors of p53-deficient Mice and Tumors of Li-Fraumeni Patients,”Cancer Res. 55:1963-1970 (1995).
Rong et al., “Tumorigenesis Induced by Coexpression of Human Hepatocyte Growth Factor and the HumanmetProtooncogene Leads to High Levels of Expression of the Ligand and Receptor,”Cell Growth Differ 4:563-569 (1993).
Rong et al., “Met Expression and Sarcoma Tumorigenicity,”Cancer Res. 55:5355-5360 (1993).
Rong et al., “Tumorigenicity of themetProto-Oncogene and the Gene for Hepatocyte Growth Factor,”Mol. Cell Biol. 12(11)5152-5158 (1992).
Rubin et al., “Hepatocyte growth factor/ scatter factor and its receptor, the cmetproto-oncogene product,”Biochim et Biophys. Acta 1155:357-371 (1993).
Santos et al., “Involvement of Hepatocyte Growth Factor in Kidney Development,”Dev. Biol. 163(2):525-529 (1994).
Schmidt et al., “Levels of Vascular Endothelial Growth Factor, Hepatocyte Growth Factor /Scatter Factor and Basic Fibroblast Growth Factor in Human Gliomas and Their Relation to Angiogenesis,”Int. J. Cancer 84:10-18 (1999).
Shima, et al., “ELISA for F-TCF (human hepatocyte growth factor/hHGF)/ fibroblast-derived tumor cytotoxic factor antigen employing monoclonal antibodies and its application to patients with liver diseases,”Gastroen. Jap. 26(4):477-482 (1991).
Sonnenberg et al., “Scatter Factor/Hepatocyte Growth Factor and Its Receptor, the c-met Tyrosine Kinase, Can Mediate a Signal Exchange between Mesenchyme and Epithelia during Mouse Development,&#
Cao Boliang
Vande Woude George
Ballard Spahr Andrews & Ingersoll LLP
Canella Karen A.
Reddig Peter J
The United States of America as represented by the Secretary, De
LandOfFree
HGF-SF monoclonal antibody combinations does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with HGF-SF monoclonal antibody combinations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HGF-SF monoclonal antibody combinations will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4035753